Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response

Dreesen, E.; Van Stappen, T.; Ballet, V.; Peeters, M.; Compernolle, G.; Tops, S.; Van Steen, Kristel; Van Assche, G.; Ferrante, M.; Vermeire, S.; Gils, A.

doi:10.1111/apt.14452

Article (Scientific journals)

Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response

Dreesen, E.; Van Stappen, T.; Ballet, V. et al.

2018 • In Alimentary Pharmacology and Therapeutics, 47 (3), p. 346-355

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/225151

DOI
10.1111/apt.14452

PubMed
29226370

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Dreesen_et_al-2018-Alimentary_Pharmacology_%26_Therapeutics.pdf

Publisher postprint (935.79 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Article; Crohn disease

Abstract :

[en] Background: The presence of antibodies towards infliximab (ATI) is associated with lower infliximab (IFX) trough concentrations and loss of response. IFX treatment intensification is effective for restoring response in most, but not all patients with Crohn's disease (CD). Aim: To compare outcome, pharmacokinetics and immunogenicity of treatment intensification strategies in patients with CD who lost clinical response to IFX. Methods: A retrospective cohort study was conducted, including 103 patients with CD who lost clinical response during IFX maintenance therapy and therefore received a double dose IFX (10 mg/kg) and/or a next infusion after a shortened interval. IFX and ATI concentrations were measured in consecutive trough samples, just before (T0) and after (T+1) treatment intensification. Results: Clinical response (physicians' global assessment) and biological response and remission (CRP) were restored in 63%, 42% and 24% of patients (evaluated at T+1). Treatment intensification increased IFX trough concentrations from 1.2 μg/mL [0.3-3.6] at T0 to 3.6 μg/mL [0.5-10.2] at T+1 (P <.0001). Using a drug tolerant assay, ATI were detected in the T0 sample of 47% of patients. ATI negatively impacted the achieved IFX trough concentration (Spearman r −0.57, P <.0001) and the probability of clinical response (P = 0.034) at T+1. When ATI were quantifiable but <282 ng/mL eq. at T0, combined interval shortening and dose doubling was more effective for restoring therapeutic IFX trough concentrations (≥3 μg/mL at T+1) than dose doubling alone, which in turn was more effective than interval shortening alone (P <.001). Conclusion: Antibodies towards infliximab can guide clinical decision-making on treatment intensification. © 2017 John Wiley & Sons Ltd

Research center :

UCB Pharma

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Dreesen, E.; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

Van Stappen, T.; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

Ballet, V.; Translational Research in GastroIntestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium, Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium

Peeters, M.; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

Compernolle, G.; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

Tops, S.; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

Van Steen, Kristel ; Université de Liège - ULiège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique

Van Assche, G.; Translational Research in GastroIntestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium, Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium

Ferrante, M.; Translational Research in GastroIntestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium, Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium

Vermeire, S.; Translational Research in GastroIntestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium, Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium

Gils, A.; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

Language :

English

Title :

Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response

Publication date :

2018

Journal title :

Alimentary Pharmacology and Therapeutics

ISSN :

0269-2813

eISSN :

1365-2036

Publisher :

Blackwell Publishing Ltd

Volume :

Issue :

Pages :

346-355

Peer reviewed :

Peer Reviewed verified by ORBi

Name of the research project :

TBM grant number T003716N

Funders :

FWO - Fonds Wetenschappelijk Onderzoek Vlaanderen [BE]
Ferring Pharmaceuticals [CH]
Celgene [US-NJ] [US-NJ]
MSD - Meso Scale Diagnostics [US-MD] [US-MD]
LFA - Lupus Foundation of America [US-DC] [US-DC]
KU Leuven - Katholieke Universiteit Leuven [BE]
Novartis [BE]
BMS - Bristol-Myers Squibb [BE]
AbbVie [BE]
Pfizer [US-NY] [US-NY]
Chiesi Farmaceutici Spa [IT]
VLAIO - Agentschap Innoveren & Ondernemen [BE]
Janssen Pharmaceutica [BE]
Abbott [FR]
MSD - Merck Sharp and Dohme [BE]

Available on ORBi :

since 13 June 2018

Statistics

Number of views

64 (3 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30:1443-1453.
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009;104:760-767.
D'Haens GR, Panaccione R, Higgins PDR, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199-212.
Dreesen E, Gils A, Vermeire S. Pharmacokinetic modeling and simulation of biologicals in inflammatory bowel disease: the dawning of a new era for personalized treatment. Curr Drug Targets. 2016; [Epub ahead of print].
Afif W, Loftus EV, Faubion W, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133-1139.
Steenholdt C, Bendtzen K, Brynskov J, et al. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease. J Crohns Colitis. 2015;9:238-245.
Kopylov U, Mantzaris GJ, Katsanos KH, et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther. 2011;33:349-357.
Chaparro M, Martínez-Montiel P, van Domselaar M, et al. Intensification of infliximab therapy in Crohn's disease: efficacy and safety. J Crohns Colitis. 2012;6:62-67.
Lin KK, Velayos F, Fisher E, Terdiman JP. Durability of infliximab dose intensification in Crohn's disease. Dig Dis Sci. 2012;57:1013-1019.
Katz L, Gisbert JP, Manoogian B, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis. 2012;18:2026-2033.
Hendler SA, Cohen BL, Colombel JF, Sands BE, Mayer L, Agarwal S. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy. J Crohns Colitis. 2015;9:266-275.
Nagata Y, Esaki M, Umeno J, et al. Therapeutic strategy for Crohn's disease with a loss of response to infliximab: a single-center retrospective study. Digestion. 2015;91:50-56.
Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1385-1397.
Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2007;26:1509-1520.
Van Stappen T, Brouwers E, Tops S, et al. Generation of a highly specific monoclonal anti-infliximab antibody for harmonization of TNF-coated infliximab assays. Ther Drug Monit. 2015;37:479-485.
Van Stappen T, Bollen L, Vande Casteele N, et al. Rapid test for infliximab drug concentration allows immediate dose adaptation. Clin Transl Gastroenterol. 2016;7:e206.
Van Stappen T, Vande Casteele N, Van Assche G, Ferrante M, Vermeire S, Gils A. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial. Gut. 2017; [Epub ahead of print].
Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:1-8.
Svetunkov I. Smooth: Forecasting Using Smoothing Functions. R Package Version 2.0.0. https://CRAN.R-project.org/package=smoothPublished2017. Accessed July 19, 2017.
Fox J, Weisberg S. An {R} Companion to Applied Regression, Second Edition. Thousand Oaks CA: Sage. http://socserv.socsci.mcmaster.ca/jfox/Books/Companion 2011, Accessed July 19, 2017.
Calcagno V. Glmulti: Model Selection and Multimodel Inference Made Easy. R Package Version 1.0.7. https://CRAN.R-project.org/package=glmulti 2013. Accessed July 19, 2017.
Lumley T based on Fortran code by Miller A. Leaps: Regression Subset Selection. R Package Version 3.0. https://CRAN.R-project.org/package=leaps 2017. Accessed July 19, 2017.
Wickham H. Ggplot2: elegant Graphics for Data Analysis. New York: Springer-Verlag; 2009:213.
Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011;33:987-995.
Khanna R, Sattin BD, Afif W, et al. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:447-459.
Moss AC. Editorial: adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease. Aliment Pharmacol Ther. 2014;40:1249.
Ding NS, Hart A, de Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease-algorithm for practical management. Aliment Pharmacol Ther. 2016;43:30-51.
Suzuki Y, Matsui T, Ito H, et al. Circulating interleukin 6 and albumin, and infliximab levels are good predictors of recovering efficacy after dose escalation infliximab therapy in patients with loss of response to treatment for Crohnʼs disease. Inflamm Bowel Dis. 2015;21:2114-2122.
Hibi T, Sakuraba A, Watanabe M, et al. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease. Inflamm Bowel Dis. 2012;18:1480-1487.
Vande Casteele N, Ferrante M, van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148:1320-1329.
Afonso J, Lopes S, Gonçalves R, et al. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. Aliment Pharmacol Ther. 2016;44:684-692.
Lu J, Spasic D, Delport F, et al. A rapid immunoassay for detection of infliximab in whole blood using a fiber-optic SPR biosensor. Anal Chem. 2017;89:3664-3671.
Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:444-447.
Vermeire S, Noman M, van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231.
Dumitrescu G, Amiot A, Seksik P, et al. The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab. Aliment Pharmacol Ther. 2015;42:1192-1199.
Ungar B, Kopylov U, Engel T, et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther. 2017;45:276-282.